Senti Biosciences, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$22K
R&D
$38M
D&A
$4M
Operating Income
$-69M
EBITDA
$-65M
Interest Expense
$927K
Tax Provision
$0
Net Income
$-61M
Operating Margin
-312631.8%
Net Margin
-279263.6%
Deferred Tax Assets
—
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$99M
Tax Credit Carryforwards
$12M
NOL Carryforwards
$70M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost
$5M
Revenue YoY Variation
-100.0%
Income YoY Variation
-12.7%